Abstract
The Cyclin D1(CCND1) G870A polymorphism may be associated with breast cancer, but the evidence from individual studies is inconclusive. The aim of this study was to investigate the correlation between the CCND1 G870A polymorphism and breast cancer risk in a meta-analysis. We searched Pubmed and analysed 11 articles on 5,528 cases and 5,353 controls before February 1, 2012. we found there are significant association for AA versus GG and AA versus GA/GG. No significant associations were found for GA versus GG, GA/AA versus GG. There are significant association for AA versus GG ,and AA versus GA/GG in Caucasians. We didn't find any significant main effects for G870A polymorphism on breast cancer risk either in recessive or dominant models in Asians. This meta-analysis suggests that AA of the CCND1 G870A polymorphism is associated with breast cancer susceptibility.
Highlights
Materials and MethodsCyclin D1(CCND1), a member of the D-type cyclin family, is the main cyclin that regulates the G1 phase of the cell cycle
Inclusion criteria The following inclusion criteria were used for the literature selection in our meta-analysis: (a) use a case-control design; (b) evaluation of the CCND1 polymorphism and breast cancer risk; (c) have available genotype frequencies for both patients and control populations; and(d) the control in the group were in agreement of Hardy-Weinberg equilibrium (HWE)
We found that AA genotypes of the CCND1 G870A polymorphism were significantly associated with breast cancer risk
Summary
Materials and MethodsCyclin D1(CCND1), a member of the D-type cyclin family, is the main cyclin that regulates the G1 phase of the cell cycle. Background: The Cyclin D1(CCND1) G870A polymorphism may be associated with breast cancer, but the evidence from individual studies is inconclusive. The aim of this study was to investigate the correlation between the CCND1 G870A polymorphism and breast cancer risk in a meta-analysis.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
